Search results for Her2

HER2/ErbB2 (29D8) Rabbit Monoclonal Antibody (Alexa Fluor^®647 Conjugate)#12965, Cell Signaling Technology (CST), 12965

HER2/ErbB2 (29D8) Rabbit Monoclonal Antibody (Alexa Fluor^®647 Conjugate) detects endogenous levels of total ErbB2 protein. This antibody conjugate does not cross-react with related kinases.

HER2 (pY1112) Antibody, Abbexa, abx031866

ErbB2 is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors.

HER2 / ErbB2 Antibody, Abbexa, abx233834

HER2/ErbB2 Antibody is a Rabbit Polyclonal against HER2/ErbB2.

HER2 (pY1112) Antibody, Abbexa, abx119366

HER2 (pY1112) Antibody is a Rabbit Polyclonal antibody against HER2 (pY1112).

HER2 / ErbB2 Antibody, Abbexa, abx233835

HER2/ErbB2 Antibody is a Mouse Monoclonal against HER2/ErbB2.

Her2 / ErbB2 antibody, Genetex, GTX87531

HER2 / ErbB2 Antibody, Abbexa, abx233833

HER2/ErbB2 Antibody is a Rabbit Polyclonal against HER2/ErbB2.

M802 Biosimilar – Anti-Bispecific mAb – Research Grade, ProteoGenix, PX-TA1899

Description of M802 Biosimilar - Anti-Bispecific mAb - Research Grade M802 Biosimilar – Anti-Bispecific mAb – Research Grade: A Revolutionary Treatment for Multiple Diseases The M802 Biosimilar is a groundbreaking antibody therapy that targets multiple diseases. This research grade medication is a biosimilar of the widely used anti-bispecific monoclonal antibody (mAb). It has been developed using advanced biotechnology and has shown promising results in preclinical trials. In this article, we will explore the structure, activity, and potential applications of M802 Biosimilar in the field of medicine. Structure of M802 Biosimilar M802 Biosimilar is a monoclonal antibody, which means it is a type of protein that is produced in a laboratory to mimic the antibodies naturally produced by the immune system. It is a biosimilar of the anti-bispecific mAb, which is a type of antibody that targets two different antigens simultaneously. The structure of M802 Biosimilar is similar to the anti-bispecific mAb, with some minor differences that allow it to target multiple diseases. The M802 Biosimilar is composed of two heavy chains and two light chains, which are connected by disulfide bonds. These chains are made up of amino acids, which are arranged in a specific sequence to form the unique structure of the antibody. The variable region of the antibody, which is responsible for binding to the target antigens, is highly specific and can recognize a wide range of disease-causing molecules. Activity of M802 Biosimilar The primary function of M802 Biosimilar is to bind to specific antigens and neutralize their activity. This is achieved through the binding of the variable region of the antibody to the target antigens, which prevents them from interacting with their respective receptors and causing disease. In addition to this, M802 Biosimilar also activates the immune system to eliminate the bound antigens, further enhancing its therapeutic effect. One of the key features of M802 Biosimilar is its ability to target multiple diseases at once. This is made possible by the unique structure of the antibody, which allows it to bind to multiple antigens simultaneously. This makes it a highly effective treatment for diseases that involve multiple targets, such as cancer and autoimmune disorders. Applications of M802 Biosimilar M802 Biosimilar has a wide range of potential applications in the field of medicine. Its ability to target multiple diseases makes it a versatile treatment option for a variety of conditions. Some of the potential applications of M802 Biosimilar include: Cancer: M802 Biosimilar has shown promising results in preclinical trials for the treatment of various types of cancer. Its ability to target multiple antigens makes it a highly effective treatment for tumors that have multiple mutations. Autoimmune disorders: M802 Biosimilar has the potential to treat autoimmune disorders, such as rheumatoid arthritis, by targeting the specific antigens that are responsible for the disease. Infectious diseases: The ability of M802 Biosimilar to activate the immune system makes it a potential treatment for infectious diseases, such as viral infections, by enhancing the body’s natural defense mechanisms. Other diseases: M802 Biosimilar may also have applications in the treatment of other diseases, such as cardiovascular diseases, neurodegenerative disorders, and inflammatory conditions. In conclusion, the M802 Biosimilar is a revolutionary treatment option that has the potential to target multiple diseases simultaneously. Its unique structure and activity make it a highly effective therapy with a wide range of potential applications. With further research and clinical trials, M802 Biosimilar has the potential to revolutionize the treatment of various diseases and improve the lives of patients worldwide.

Pertuzumab, Affinityimmuno, ab-131-pertuzumab

Ado-trastuzumab emtansine, Affinityimmuno, ab-131-ado-trastuzumab